Cargando…

Pulmonary hypertension in hemolytic anemias

Pulmonary hypertension (PH) has been reported with nearly all forms of the inherited as well as the acquired hemolytic anemias. Recent research investigating the pathophysiology of PH in sickle cell disease and thalassemia has helped elucidate the central role of hemolysis-mediated endothelial dysfu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahl, Shannon, Vichinsky, Elliott
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948405/
https://www.ncbi.nlm.nih.gov/pubmed/20948876
http://dx.doi.org/10.3410/M2-10
_version_ 1782187463828045824
author Wahl, Shannon
Vichinsky, Elliott
author_facet Wahl, Shannon
Vichinsky, Elliott
author_sort Wahl, Shannon
collection PubMed
description Pulmonary hypertension (PH) has been reported with nearly all forms of the inherited as well as the acquired hemolytic anemias. Recent research investigating the pathophysiology of PH in sickle cell disease and thalassemia has helped elucidate the central role of hemolysis-mediated endothelial dysfunction in the development of PH in these populations. Although the most appropriate treatment of PH in patients with hemolytic anemia is not clearly defined, the associated significant increased risk of death underscores the need for randomized clinical trials in this area.
format Text
id pubmed-2948405
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29484052010-10-14 Pulmonary hypertension in hemolytic anemias Wahl, Shannon Vichinsky, Elliott F1000 Med Rep Review Article Pulmonary hypertension (PH) has been reported with nearly all forms of the inherited as well as the acquired hemolytic anemias. Recent research investigating the pathophysiology of PH in sickle cell disease and thalassemia has helped elucidate the central role of hemolysis-mediated endothelial dysfunction in the development of PH in these populations. Although the most appropriate treatment of PH in patients with hemolytic anemia is not clearly defined, the associated significant increased risk of death underscores the need for randomized clinical trials in this area. Medicine Reports Ltd 2010-02-11 /pmc/articles/PMC2948405/ /pubmed/20948876 http://dx.doi.org/10.3410/M2-10 Text en © 2010 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Wahl, Shannon
Vichinsky, Elliott
Pulmonary hypertension in hemolytic anemias
title Pulmonary hypertension in hemolytic anemias
title_full Pulmonary hypertension in hemolytic anemias
title_fullStr Pulmonary hypertension in hemolytic anemias
title_full_unstemmed Pulmonary hypertension in hemolytic anemias
title_short Pulmonary hypertension in hemolytic anemias
title_sort pulmonary hypertension in hemolytic anemias
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948405/
https://www.ncbi.nlm.nih.gov/pubmed/20948876
http://dx.doi.org/10.3410/M2-10
work_keys_str_mv AT wahlshannon pulmonaryhypertensioninhemolyticanemias
AT vichinskyelliott pulmonaryhypertensioninhemolyticanemias